innovative treatments, but at what cost?
The results of clinical trials conducted in the United States to treat patients with sickle cell disease with a treatment based on Crispr-Cas9 genome modification technology give rise to hope. This hereditary blood disease, particularly debilitating and hitherto incurable, affects several million people worldwide. But not everyone will be able to benefit from this therapeutic…